Genocea Reports Fourth Quarter and Year-End 2016 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Genocea Reports Fourth Quarter and Year-End 2016 Financial Results

Needham & Company Downgrades Genocea Biosciences (GNCA) to Hold

February 17, 2017 7:09 AM EST

Needham & Company downgraded Genocea Biosciences (NASDAQ: GNCA) from Buy to Hold, saying uncertainty around the HSV2 program is a concern.

Analyst Alan Carr commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017.... More

Genocea Biosciences (GNCA) Misses Q4 EPS by 11c

February 16, 2017 7:36 AM EST

Genocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.56), $0.11 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $0, versus $0 reported last year.

Cash, cash equivalents and investments as of December 31, 2016 were $63.4 million compared to $75.5 million as of September 30, 2016.

For earnings... More